Physician profile
John Oubre
NPI 1295945434
$1,490.23
in general payments reported to CMS, 2019-2025
14 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $57.13 · 2021: $226 · 2022: $214 · 2023: $324 · 2024: $15.12 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.19 | 2019-2025 | Wegovy |
| Amgen INC. | $222.90 | 2019-2025 | |
| Inspire Medical Systems, INC. | $178.13 | 2023-2025 | Inspire |
| Tris Pharma INC | $125.00 | 2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Intuitive Surgical, INC. | $100.00 | 2022 | |
| Exact Sciences Corporation | $88.20 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $85.50 | 2019 | |
| Array Biopharma INC | $57.13 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $42.17 | 2019 | |
| Secura Bio, INC. | $26.03 | 2021-2022 | |
| Lilly USA, LLC | $22.87 | 2019 | |
| Melinta Therapeutics, LLC | $15.54 | 2019 | |
| Dexcom, INC. | $15.12 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oubre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.